Jeanette Tetrault, MD
Internal Medicine · New Haven, CTNPI 1003841321
Payments from drug & device makers
Across 37 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$192
- Indivior Inc.$112
- Pfizer$75
- Orexo US, Inc.$68
- AbbVie$60
- Alkermes, Inc.$30
- plus $99 from 6 others
What the payments were for
- Food & beverage$636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 13 | $192 |
| Indivior Inc. | 4 | $112 |
| Pfizer | 5 | $75 |
| Orexo US, Inc. | 4 | $68 |
| AbbVie | 3 | $60 |
| Alkermes, Inc. | 2 | $30 |
| Viiv Healthcare Company | 1 | $20 |
| Neos Therapeutics, LP | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
How this compares
$636 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $3,016 |
| Levemir FlexpenInsulin Detemir | 11 | $1,726 |
| Oxycodone Hcl | 40 | $745 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $426 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $328 |
| Gabapentin | 22 | $281 |
| Clonazepam | 29 | $221 |
| Atorvastatin Calcium | 16 | $171 |
| Lisinopril | 19 | $134 |
| Rosuvastatin Calcium | 21 | $81 |
| Trazodone Hcl | 12 | $74 |
| Levothyroxine Sodium | 12 | $70 |
| Sertraline Hcl | 12 | $59 |
| Amlodipine Besylate | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New Haven
- Nancy BrownNew Haven$2.8M
- Michael SchilskyNew Haven$601K
- Marina SilveiraNew Haven$406K
- Stephen BaldassarriNew Haven$189K
- Charles Dela CruzNew Haven$161K
- Richard LiftonNew Haven$160K
- Wayne WarrenNew Haven$127K
- Maryam GondalNew Haven$114K
- Sandra SpringerNew Haven$77K
- Marcella SmithNew Haven$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.